Abstract:A rational approach was adopted to design high-potential metal-based antitumor agents. A series of organometallic Pd(ii) complexes with a general formula of [Pd{κ2(C,C)-[(C6H4-2)PPh2]CH(CO)C6H4Ph-4}{κ2(N,O)}] (N,O = alanine (Pd-A), valine (Pd-V), leucine (Pd-L), l-isoleucine (Pd-I) and phenylalanine (Pd-F)) were prepared by cyclopalladation of the phosphorus ylide, bridge cleavage reaction and subsequent chelation of natural α-amino acids. The complexes were fully identified using IR and multinuclear 1H, 13C, 31P NMR spectroscopic methods. X-ray crystallography exhibited that the Pd(ii) atom is located in a slightly distorted square-planar environment surrounded by C,C-orthometallated phosphorus ylide as well as NO-pendant amino acid functionality. In vitro cytotoxicity evaluation of new cyclometallated Pd(ii) complexes toward a human leukemia (K562) cancer cell line indicated promising results. The highest cytotoxic activity was discovered in the case of phenylalanine (CH2C6H5). IC50 values of this complex on a panel of human tumor cell lines representative of liver (HepG2), breast (SKBR-3), and ovarian (A2780-Resistance/Sensitive) cancers also indicated promising antitumor effects in comparison with standard cisplatin. The binding interaction ability of the phenylalanine-containing orthopalladated complex, as the most efficient compound, with calf-thymus deoxyribonucleic acid (CT-DNA) and bovine serum albumin (BSA) was investigated. UV-Vis spectroscopy, competitive emission titration, and circular dichroism (CD) techniques demonstrated the intercalative binding of the Pd(ii) complex with DNA. Molecular docking studies also fully agreed with the experimental data. Examination of the reactivity towards the protein BSA revealed that the static quenching mechanism of BSA intrinsic fluorescence by the Pd(ii) complex with a binding constant (Kb) of ∼105 is indicative of the high affinity of the complex. The competitive binding experiment using site markers with definite binding sites demonstrated that the hydrophobic cavities of site I (subdomain IIA) are responsible for the bimolecular interaction between protein BSA and the complex. Molecular docking studies effectively confirmed the significance of hydrophobic interactions in Pd(ii)-BSA binding. The results of this study could greatly contribute to exploring new potent metal-based anticancer drugs.

Synthesis of bimetallic palladacycles via C H bond activation: Crystal structure, DNA binding and in vitro cytotoxicity study

Palladium(II) Complexes with N,N′-Dialkyl-1,10-phenanthroline-2,9-dimathanamine: Synthesis, Characterization and Cytotoxic Activity

Anticancer behaviour of 2,2′-(pyridin-2-ylmethylene)bis(5,5-dimethylcyclohexane-1,3-dione)-based palladium(II) complex and its DNA, BSA binding propensity and DFT study

Crystal Structures, Interactions with Biomacromolecules and Anticancer Activities of Mn(II), Ni(II), Cu(II) Complexes of Demethylcantharate and 2-Aminopyridine

Potent cyclometallated Pd(II) antitumor complexes bearing α-amino acids: synthesis, structural characterization, DNA/BSA binding, cytotoxicity and molecular dynamics simulation

Synthesis and Biological Activity of Binuclear Platinum Complexes Containing Two Monofunctional Cis-[Pt(Nh3)(2)Cl](+) Units Bridged by 4,4 '-Dipyridyl Selenides or Sulfides

Comparative Linkage of Novel Anti-Tumor Pd(II) Complex with Bio-Macromulecules: Fluorescence, UV-Vis, DFT, Molecular Docking and Molecular Dynamics Simulation Studies

Crystal Structure, DNA-binding Ability and Cytotoxic Activity of Platinum(ii) 2,2′-Dipyridylamine Complexes

Mononuclear Copper(II) Complexes with Polypyridyl Ligands: Synthesis, Characterization, DNA Interactions/Cleavages and in vitro Cytotoxicity towards Human Cancer Cells

Synthesis, characterization and anticancer properties: A series of highly selective palladium(II) substituted-terpyridine complexes

Interaction with Biomacromolecules and Antiproliferative Activities of Mn(Ii), Ni(Ii), Zn(Ii) Complexes of Demethylcantharate and 2,2 '-Bipyridine

Dna-Binding Property and Antitumor Activity of A Cyclam Bridged Dinuclear Platinum(Ii) Complex

Two Novel Cadmium(ii) Complexes with Demethylcantharate and Polypyridyl: Crystal Structure, Interactions with DNA and Bovine Serum Albumin

Crystal Design, Antitumor Activity and Molecular Docking of Novel Palladium(II) and Gold(III) Complexes with a Thiosemicarbazone Ligand

Synthesis and Spectral Studies of Some New Palladium(ii) and Platinum(ii) Dithio Complexes: the Novel Crystal Structure of the Palladium(ii) Dithiocarbimato Complex

Biological Impact of Pd (II) Complexes: Synthesis, Spectral Characterization, In Vitro Anticancer, CT-DNA Binding, and Antioxidant Activities

Computational and experimental examinations of new antitumor palladium(II) complex: CT-DNA-/BSA-binding, in-silico prediction, DFT perspective, docking, molecular dynamics simulation and ONIOM

The cytotoxicity of palladium (II) complexes containing 1,2‐ or 1,4‐diazine bridging ligands on squamous cell carcinoma cells in vitro: Insights in the mechanisms of action

Synthesis, characterization, DNA/BSA-binding affinity and biological activity of dinuclear palladium(II) complexes with aromatic N-heterocyclic bridging ligand

Synthesis, substitution kinetics, DNA/BSA binding and cytotoxicity of tridentate N^E^N (E = NH, O, S) pyrazolyl palladium(II) complexes

Synthesis, characterization, anti-bacterial and anticancer activities of Palladium(II) mixed ligand complexes of 2-mercapto-5-methyl-1,3,4-thiadiazole (HmtzS) and phosphines. Crystal structure of [Pd(mtzS)2(dppf)].H2O.EtOH